{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:32:17Z","timestamp":1793716337177,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204758"],"award-info":[{"award-number":["82204758"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00861-y","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:14:11Z","timestamp":1738948451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1186","volume":"26","author":[{"given":"Huiping","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maochang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"861_CR1","doi-asserted-by":"publisher","unstructured":"Yasin A, Nguyen M, Sidhu A, Majety P, Spitz J, Asgharpour A, et al. Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: bi-directional opportunities to multiply preventive strategies. Diabetes Res Clin Pr. 2024;211:111650. https:\/\/doi.org\/10.1016\/j.diabres.2024.111650.","DOI":"10.1016\/j.diabres.2024.111650"},{"key":"861_CR2","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. https:\/\/doi.org\/10.1016\/j.diabres.2019.107843.","journal-title":"Diabetes Res Clin Pract"},{"key":"861_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/dom.13650","volume":"21","author":"E Brown","year":"2019","unstructured":"Brown E, Rajeev SP, Cuthbertson DJ, Wilding JPH. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21:9\u201318. https:\/\/doi.org\/10.1111\/dom.13650.","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"861_CR4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","volume":"72","author":"TA Zelniker","year":"2018","unstructured":"Zelniker TA, Braunwald E. Cardiac and Renal effects of Sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(15):1845\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.040.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"861_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"15","key":"861_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"2","key":"861_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"E-KCG The","year":"2023","unstructured":"The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"3","key":"861_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00592-022-02015-6","volume":"60","author":"ZC He","year":"2023","unstructured":"He ZC, Lam K, Zhao WX, Yang S, Li Y, Mo JY, et al. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis\/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment. Acta Diabetol. 2023;60(3):401\u201311. https:\/\/doi.org\/10.1007\/s00592-022-02015-6.","journal-title":"Acta Diabetol"},{"issue":"11","key":"861_CR9","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s11255-022-03211-7","volume":"54","author":"G Chen","year":"2022","unstructured":"Chen G, Li XL, Cui QX, Zhou YZ, Zhao B, Mei D, et al. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study. Int Urol Nephrol. 2022;54(11):2949\u201357. https:\/\/doi.org\/10.1007\/s11255-022-03211-7.","journal-title":"Int Urol Nephrol"},{"key":"861_CR10","doi-asserted-by":"publisher","unstructured":"Fadini GP, Sarangdhar M, De Ponti F, Avogaro A, Raschi E. Pharmacovigilance assessment of the association between Fournier\u2019s gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2019;7(1):e000725. https:\/\/doi.org\/10.1136\/bmjdrc-2019-000725.","DOI":"10.1136\/bmjdrc-2019-000725"},{"issue":"9","key":"861_CR11","doi-asserted-by":"publisher","first-page":"102664","DOI":"10.1016\/j.cpcardiol.2024.102664","volume":"49","author":"KB Bhanushali","year":"2024","unstructured":"Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors- safety review of real-world data & randomized clinical trials. Curr Probl Cardiol. 2024;49(9):102664. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102664.","journal-title":"Curr Probl Cardiol"},{"key":"861_CR12","doi-asserted-by":"publisher","unstructured":"Shu YM, He XC, Liu YX, Wu P, Zhang QL, Real-World A. Clin Epidemiol. 2022;14:789\u2013802. https:\/\/doi.org\/10.2147\/Clep.S365513. Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.","DOI":"10.2147\/Clep.S365513"},{"issue":"5","key":"861_CR13","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.jaip.2023.01.027","volume":"11","author":"X Lin","year":"2023","unstructured":"Lin X, Yang J, Weng L, Lin W. Differences in Hypersensitivity Reactions to Iodinated Contrast Media: analysis of the US Food and Drug Administration adverse event reporting System Database. J Allergy Clin Immunol Pract. 2023;11(5):1494\u2013e5026. https:\/\/doi.org\/10.1016\/j.jaip.2023.01.027.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"861_CR14","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ijc.34848","volume":"154","author":"H Chen","year":"2024","unstructured":"Chen H, Yang G, Ma J. Ocular toxicity associated with anti-HER2 agents in breast cancer: a pharmacovigilance analysis using the FAERS database. Int J Cancer. 2024;154(9):1616\u201325. https:\/\/doi.org\/10.1002\/ijc.34848.","journal-title":"Int J Cancer"},{"key":"861_CR15","doi-asserted-by":"publisher","first-page":"1339505","DOI":"10.3389\/fphar.2024.1339505","volume":"15","author":"H Hu","year":"2024","unstructured":"Hu H, Fu Z, Liu J, Zhang C, Li S, Zhang Y, et al. Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database. Front Pharmacol. 2024;15:1339505. https:\/\/doi.org\/10.3389\/fphar.2024.1339505.","journal-title":"Front Pharmacol"},{"issue":"1","key":"861_CR16","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","volume":"12","author":"Y Yin","year":"2022","unstructured":"Yin Y, Shu Y, Zhu J, Li F, Li J. A real-world pharmacovigilance study of FDA adverse event reporting System (FAERS) events for osimertinib. Sci Rep. 2022;12(1):19555. https:\/\/doi.org\/10.1038\/s41598-022-23834-1.","journal-title":"Sci Rep"},{"issue":"10","key":"861_CR17","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1007\/s00431-023-05146-2","volume":"182","author":"M Zhang","year":"2023","unstructured":"Zhang M, Li H, Huang L, Liu Y, Jiao XF, Zeng L, et al. Drug-associated kidney injury in children: a disproportionality analysis of the FDA adverse event reporting system. Eur J Pediatr. 2023;182(10):4655\u201361. https:\/\/doi.org\/10.1007\/s00431-023-05146-2.","journal-title":"Eur J Pediatr"},{"issue":"8","key":"861_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519\u201323. https:\/\/doi.org\/10.1002\/pds.1001.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"861_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"861_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321. https:\/\/doi.org\/10.1007\/s002280050466.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"861_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2307\/2686093","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53(3):177\u201390. https:\/\/doi.org\/10.2307\/2686093.","journal-title":"Am Stat"},{"key":"861_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zhou LY, Shen Y, Zhou Q, Ji YY, Zhu HH. Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. J Affect Disorders. 2024;346:223\u20139. https:\/\/doi.org\/10.1016\/j.jad.2023.11.025.","journal-title":"J Affect Disorders"},{"issue":"10","key":"861_CR23","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s40265-018-0937-z","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton JE, Empagliflozin. A review in type 2 diabetes. Drugs. 2018;78(10):1037\u201348. https:\/\/doi.org\/10.1007\/s40265-018-0937-z.","journal-title":"Drugs"},{"issue":"16","key":"861_CR24","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s40265-022-01778-0","volume":"82","author":"JE Frampton","year":"2022","unstructured":"Frampton JE, Empagliflozin. A review in symptomatic chronic heart failure. Drugs. 2022;82(16):1591\u2013602. https:\/\/doi.org\/10.1007\/s40265-022-01778-0.","journal-title":"Drugs"},{"key":"861_CR25","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J. 2023;16(8):1187\u201398. https:\/\/doi.org\/10.1093\/ckj\/sfad082.","DOI":"10.1093\/ckj\/sfad082"},{"issue":"7","key":"861_CR26","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s00125-024-06126-3","volume":"67","author":"PT Htoo","year":"2024","unstructured":"Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, et al. Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia. 2024;67(7):1328\u201342. https:\/\/doi.org\/10.1007\/s00125-024-06126-3.","journal-title":"Diabetologia"},{"issue":"3","key":"861_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2213-8587(22)00387-4","volume":"11","author":"LM Laffel","year":"2023","unstructured":"Laffel LM, Danne T, Klingensmith GJ, Tamborlane W, Willi S, Zeitler P, et al. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endo. 2023;11(3):169\u201381. https:\/\/doi.org\/10.1016\/S2213-8587(22)00387-4.","journal-title":"Lancet Diabetes Endo"},{"issue":"6","key":"861_CR28","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2337\/dc21-2034","volume":"45","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, et al. Safety of Empagliflozin in patients with type 2 diabetes and chronic kidney disease: pooled analysis of placebo-controlled clinical trials. Diabetes Care. 2022;45(6):1445\u201352. https:\/\/doi.org\/10.2337\/dc21-2034.","journal-title":"Diabetes Care"},{"issue":"7","key":"861_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11892-020-01307-x","volume":"20","author":"BM Bonora","year":"2020","unstructured":"Bonora BM, Avogaro A, Fadini GP. Euglycemic Ketoacidosis. Curr Diab Rep. 2020;20(7):25. https:\/\/doi.org\/10.1007\/s11892-020-01307-x.","journal-title":"Curr Diab Rep"},{"issue":"6","key":"861_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","volume":"173","author":"A Douros","year":"2020","unstructured":"Douros A, Lix LM, Fralick M, Dell\u2019Aniello S, Shah BR, Ronksley PE, et al. Sodium-glucose Cotransporter-2 inhibitors and the risk for Diabetic Ketoacidosis A Multicenter Cohort Study. Ann Intern Med. 2020;173(6):417\u2013. https:\/\/doi.org\/10.7326\/M20-0289.","journal-title":"Ann Intern Med"},{"issue":"12","key":"861_CR31","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to Insulin Therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018;41(12):2560\u20139. https:\/\/doi.org\/10.2337\/dc18-1749.","journal-title":"Diabetes Care"},{"key":"861_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajem.2021.02.015","volume":"44","author":"B Long","year":"2021","unstructured":"Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management. Am J Emerg Med. 2021;44:157\u201360. https:\/\/doi.org\/10.1016\/j.ajem.2021.02.015.","journal-title":"Am J Emerg Med"},{"key":"861_CR33","doi-asserted-by":"publisher","unstructured":"Bardhi O, Bloom MD, Sattari M. Euglycaemic diabetic ketoacidosis in a patient with pancreatitis and type 2 diabetes on empagliflozin. BMJ Case Rep. 2022;15(6):e247921. https:\/\/doi.org\/10.1136\/bcr-2021-247921.","DOI":"10.1136\/bcr-2021-247921"},{"key":"861_CR34","doi-asserted-by":"publisher","unstructured":"Yu XF, Zhang SF, Zhang L. Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis. Int J Endocrinol. 2018;2018:7074868. https:\/\/doi.org\/10.1155\/2018\/7074868.","DOI":"10.1155\/2018\/7074868"},{"issue":"3","key":"861_CR35","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s13300-019-0611-9","volume":"10","author":"J Shen","year":"2019","unstructured":"Shen J, Yang J, Zhao B. A survey of the FDA\u2019s adverse event reporting system database concerning urogenital tract infections and sodium glucose Cotransporter-2 inhibitor use. Diabetes Ther. 2019;10(3):1043\u201350. https:\/\/doi.org\/10.1007\/s13300-019-0611-9.","journal-title":"Diabetes Ther"},{"issue":"1","key":"861_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2337\/cd21-0015","volume":"40","author":"BA Tran","year":"2022","unstructured":"Tran BA, Updike WH, Bullers K, Serag-Bolos E. Sodium-glucose cotransporter 2 inhibitor Use Associated with Fournier\u2019s Gangrene: a review of Case reports and spontaneous post-marketing cases. Clin Diabetes. 2022;40(1):78\u201386. https:\/\/doi.org\/10.2337\/cd21-0015.","journal-title":"Clin Diabetes"},{"issue":"1","key":"861_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00592-016-0892-7","volume":"54","author":"M Monami","year":"2017","unstructured":"Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(1):19\u201336. https:\/\/doi.org\/10.1007\/s00592-016-0892-7.","journal-title":"Acta Diabetol"},{"issue":"2","key":"861_CR38","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/dom.13900","volume":"22","author":"GA Silverii","year":"2020","unstructured":"Silverii GA, Dicembrini I, Monami M, Mannucci E. Fournier\u2019s gangrene and sodium-glucose co-transporter-2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020;22(2):272\u20135. https:\/\/doi.org\/10.1111\/dom.13900.","journal-title":"Diabetes Obes Metab"},{"key":"861_CR39","doi-asserted-by":"publisher","first-page":"3695101","DOI":"10.1155\/2020\/3695101","volume":"2020","author":"Y Hu","year":"2020","unstructured":"Hu Y, Bai Z, Tang Y, Liu R, Zhao B, Gong J, et al. Fournier Gangrene Associated with Sodium-glucose Cotransporter-2 inhibitors: a Pharmacovigilance Study with Data from the U.S. FDA adverse event reporting system. J Diabetes Res. 2020;2020:3695101. https:\/\/doi.org\/10.1155\/2020\/3695101.","journal-title":"J Diabetes Res"},{"key":"861_CR40","unstructured":"Us Food and Drug Administration. Potential signals of serious risks\/new safety information identified by the FDA adverse event reporting system (FAERS). 2016. Available at: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/april-june-2016-potential-signals-serious-risksnew-safety-information-identified-fda-adverse-event."},{"key":"861_CR41","unstructured":"Health Canada. Summary safety review- Sodium\/glucose cotransporter 2 (SGLT2) inhibitors - assessing the potential risk of inflammation of the pancreas (acute and chronic pancreatitis). 2022. Available at: https:\/\/hpr-rps.hres.ca\/reg-content\/summary-safety-review-detail.php?lang=en%26linkID=SSR00204."},{"issue":"6","key":"861_CR42","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s11096-022-01476-7","volume":"44","author":"H Palapra","year":"2022","unstructured":"Palapra H, Viswam SK, Kalaiselvan V, Undela K. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports. Int J Clin Pharm-Net. 2022;44(6):1425\u201333. https:\/\/doi.org\/10.1007\/s11096-022-01476-7.","journal-title":"Int J Clin Pharm-Net"},{"issue":"15","key":"861_CR43","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1080\/14656566.2016.1232395","volume":"17","author":"H Ito","year":"2016","unstructured":"Ito H, Shinozaki M, Nishio S, Abe M. SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. Expert Opin Pharmaco. 2016;17(15):2073\u201384. https:\/\/doi.org\/10.1080\/14656566.2016.1232395.","journal-title":"Expert Opin Pharmaco"},{"key":"861_CR44","doi-asserted-by":"publisher","unstructured":"Zhou X, Ye XF, Guo XJ, Liu DX, Xu JF, Hu FY, et al. Safety of SGLT2 inhibitors: a pharmacovigilance study from 2013 to 2021 based on FAERS. Front Pharmacol. 2021;12:766125. https:\/\/doi.org\/10.3389\/fphar.2021.766125.","DOI":"10.3389\/fphar.2021.766125"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00861-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00861-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00861-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:14:15Z","timestamp":1738948455000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00861-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00861-y","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not provided for this study on human participants because FAERS (FDA Adverse Event Reporting System) is publicly available and anonymous database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}